Tokyo, September 16, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year as an index component of the Dow Jones Sustainability Asia Pacific Index, the Asia Pacific version of the Dow Jones Sustainability Indices (“DJSI”) and one of the world’s premier indices for Socially Responsible Investment (“SRI”).

The DJSI, launched jointly by Dow Jones & Company of the United States and RobecoSAM AG of Switzerland, is a leading SRI index which assesses and selects leading sustainability-driven companies in terms of economic, environmental, and social criteria.

Specifically designed for companies in the developed Asia Pacific markets including Japan, the Dow Jones Sustainability Asia Pacific Index has selected 146 companies, including 68 Japanese companies, which are leading the way in terms of sustainability among approximately 600 companies in the region.

In addition to the DJSI, Astellas has also been selected for the fifth consecutive year to be included in the FTSE4Good Index Series, one of the world’s premier indices for SRI.

Astellas will continue to fulfill its corporate social responsibilities through a range of corporate activities including the provision of pharmaceutical products to address unmet medical needs, and will remain committed to supporting the sustainable development of society and consequently enhancing its enterprise value.